Market research
HUGE FSD Pharma Inc Class B
NASDAQ USD Healthcare
Latest close
As of 05 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 67K
- P/E ratio
- Not available
- Analyst target
- 2.6
- Dividend yield
- Not available
- Beta
- 0.85
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA35954B2066
- Market cap
- 67K
- P/E ratio
- Not available
- Analyst target
- 2.6
- Dividend yield
- Not available
- Beta
- 0.85
About
About FSD Pharma Inc Class B
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.
Research context
FSD Pharma Inc Class B appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the HUGE discussion.
5 years, 7 months ago
From a valuation standpoint, the stock is 92.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 105.0.
Based on the above factors, FSD Pharma Inc gets an overall score of 1/5.